aTyr Pharma up as dosing starts in lung disease therapy trial

aTyr Pharma

27/09/2022 13:50

** Drug developer aTyr Pharma Inc shares  LIFE.O  rise 8.83%
to $3.08 before the bell
    ** Co doses first patient in a late-stage trial testing
efficacy and safety of its lead lung disease candidate, 
efzofitimod  urn:newsml:reuters.com:*:nGNX59DS5r 
    ** Study intends to enroll 264 persons with pulmonary
sarcoidosis, a major form of lung disease that affects the
tissue and space around the air sacs in the lungs
    ** All 6 brokerages covering the stock rate "buy" or higher;
their median PT is $20
    ** Up to Monday's close, stock down 71.41%
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))